NovoCure (NASDAQ: NVCR) net income
NovoCure reported a net loss of $136.2m for fiscal 2025; in fiscal 2024 it reported a net loss of $168.6m. Earnings per share were −$1.22.
NovoCure's best year of the last 10 was fiscal 2020. It reported a loss in 9 of those 10 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$136.2m | — | — | −$1.22 |
| 2024 | −$168.6m | — | −27.9% | −$1.56 |
| 2023 | −$207.0m | — | −40.6% | −$1.95 |
| 2022 | −$92.5m | — | −17.2% | −$0.88 |
| 2021 | −$58.4m | −394.6% | −10.9% | −$0.56 |
| 2020 | $19.8m | — | 4.0% | $0.20 |
| 2019 | −$7.2m | — | −2.1% | — |
| 2018 | −$63.6m | — | −25.6% | — |
| 2017 | −$61.7m | — | −34.8% | — |
| 2016 | −$131.8m | — | −159.1% | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
NovoCure net income compared with its sector
By net income for its latest fiscal year, NovoCure ranks 367th of the 501 US health care companies with a page on Celsmar.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 365th | Maravai LifeSciences | −$130.8m | −70.4% |
| 366th | Kestra Medical Technologies | −$131.6m | −138.4% |
| 367th | NovoCure | −$136.2m | — |
| 368th | Zentalis Pharmaceuticals | −$137.1m | — |
| 369th | Bicara Therapeutics | −$138.0m | — |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of NovoCure
- How much did NovoCure earn in fiscal 2025?
- NovoCure reported a net loss of $136.2m for fiscal 2025. In fiscal 2024 it reported a net loss of $168.6m.
- What are the earnings per share of NovoCure?
- They were −$1.22 in fiscal 2025, compared with −$1.56 in fiscal 2024.
- What was the most profitable year for NovoCure?
- Of its last 10 fiscal years, fiscal 2020, with $19.8m.
- Where does NovoCure rank in its sector by net income?
- It ranks 367th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for NovoCure come from?
- From the annual report (Form 10-K) that NovoCure files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that NovoCure files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on NovoCure: the NovoCure page · annual accounts · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.